Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Spartrapon Mar 05, 2021 3:00pm
90 Views
Post# 32730342

RE:RE:RE:RE:New Corporate Presentation is up

RE:RE:RE:RE:New Corporate Presentation is up

Well I assumed "conducted" (footnotes on page 6 and 7) meant TH is footing the bill.

Maybe not, or maybe costs are shared..but then wouldn't the corporate document make that unambiguous?

SPCEO1 wrote: Where did you see that TH is footing the bill for the IM Trogarzo trial?
 

Spartrap wrote:

Was it known that the Trogarzo's IM study is to be conducted by Thera?

Wonder how much this is going to cost, on top of the two other european trog studies.. (ouch)

 

scarlet1967 wrote:

 

For R&D looking through it quickly they added the fast track for PDC and study may proceed for both protocols.
The commercializing strategies seems to have few new additions, note they are saying the Trogarzo market opportunity could be as much as US!
“New Go-to-Market Strategy Underpinned by Sales Force Reorganization and Targeted Patient / Prescriber Education.
Leverage existing localized KOL relationships to capture HIV market opportunities, which could scale to parity with the U.S.
Targeted and frequent educational initiatives to key KOLs, patients and the HIV community.”
 
SPCEO1 wrote: https://www.theratech.com/wp-content/uploads/2021/03/Corporate-Presentation_Theratehnologies_March-2021.pdf
 

 

 




<< Previous
Bullboard Posts
Next >>